Replies to post #736808 on NorthWest Biotherapeutics Inc (NWBO)

[norisknorewards]

The facts are you short and distort. For all the newbies...

[skitahoe]

What we don't know is whether today Dr Liau and-or the company can differentiate between PFS and Pseudoprogression.  If they now can do it routinely with methods accepted by the regulators, PFS may once again be an accepted trial goal.

Gary 

[barnstormer]

Just one more poster HyGro, presenting their speculation and opinion as facts without any factual basis.

[Roman516]

No Gro, the OS data matters more!
The PFS is a joke as the OS results are what matters the most! Your broken record needs to be tossed out. DCVax-L works, and you know this. The MMs are corrupt, and you know this as well, IMO.

[DocLee]

Hygro, your desperation is clearly showing in your attempt to resurrect yet again the hoary old discredited claim that the phase 3 trial failed because it did not meet the primary endpoint of Progression Free Survival (PFS). Your claim that this is supported by Prof Liau's decision to use PFS as the endpoint for the current SPORE/UCLA trial is illogical and ludicrous.

I reiterate that PFS as the endpoint was not the problem, it was the method used for assessing whether the tumour had recurred or not that was at fault. Tumour recurrence was assessed by simple X-ray imaging but early on it was found to be flawed as it was unable to tell the difference accurately between tumour recurrence and tumour infiltration by activated T-cells. It was a technical failure, not a failure of treatment that forced the abandonment of PFS as the end-point.

Your claim that abandoning PFS was done to avoid revealing that the treatment had failed and that this is now validated by Prof Liau's use of PFS is illogical; it is a non-sequitur - there is nothing logically to connect the two occurrences. All it shows is that it is a sign of your desperation to prove that black is white.

If PFS is being used in the current trial it is because it is a reasonable avatar for OS and can shorten trials significantly. Additionally, believe it or not, the technology for differentiating tumour recurrence from tumour infiltration has advanced considerably since the the original phase 3 clinical trial was designed. Simple X-rays are not used. Instead the SPORE/UCLA study is investigating a range of more advanced imaging techniques as shown on the National Cancer Institute's web page: https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h08 They include such tools as: MRI (several different types) and immunoPET et al